Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 13,308 Cr.
- Current Price ₹ 556
- High / Low ₹ 737 / 469
- Stock P/E 34.8
- Book Value ₹ 98.5
- Dividend Yield 0.00 %
- ROCE 29.0 %
- ROE 26.9 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 88.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of Nifty 500 BSE Healthcare BSE IPO Nifty Smallcap 250 Nifty 500 Multicap 50:25:25
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|
| 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,757 | |
| 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,231 | |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 526 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% |
| 7 | -102 | -3 | -21 | 58 | 79 | 107 | |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 | 31 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 78 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 524 |
| Tax % | 45% | 191% | 23% | 28% | 27% | 27% | |
| 14 | -12 | 149 | 163 | 266 | 337 | 384 | |
| EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.34 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 39% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 88% |
| 3 Years: | 32% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 |
| Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,312 |
| 147 | 483 | 51 | 66 | 502 | 490 | 88 | |
| 108 | 222 | 220 | 524 | 638 | 627 | 576 | |
| Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,024 |
| 104 | 119 | 86 | 138 | 664 | 646 | 632 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | 13 | -0 | 120 | 614 | 796 | 917 |
| 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,475 | |
| Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,024 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 65 | 22 | 172 | 297 | 130 | 508 | |
| -18 | -16 | -81 | -158 | -896 | -326 | |
| -21 | 136 | -132 | 233 | 333 | -66 | |
| Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 |
| Inventory Days | ||||||
| Days Payable | ||||||
| Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 |
| Working Capital Days | 23 | 64 | 53 | 16 | 45 | 40 |
| ROCE % | 37% | 55% | 46% | 33% | 29% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Officials of the Company will be meeting Investors / Analysts .
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - The officials of the Company will be meeting 1x1(In Person) Investors / Analysts on 25th February 2025 from 9:00 AM IST in Mumbai.
-
Intimation Of Resolution Proposed To Be Passed By Circulation.
18 Feb - Resolution for share allotment under RSU and ESOP plans.
-
Intimation Regarding The Change Of Name Of Registrar And Transfer Agent ('RTA') From 'Link Intime India Private Limited' To 'MUFG Intime India Private Limited'
13 Feb - Change of RTA name to MUFG Intime India.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Feb - Schedule of investor/analyst meeting on February 21, 2025.
Concalls
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.